Director / PDMR Shareholding

14^th Dec 2015

EKF Diagnostics Holdings plc (AIM: EKF), announces that it was informed on 11 December that Paul Foulger, who recently resigned from the Board as Finance Director and will leave the Company at the end of the year, had purchased 250,000 shares in EKF on that day at an average price of 11.56p.

Following this purchase Paul’s total shareholding is 3,738,589 ordinary shares, which represents 0.89% of the Company's issued share capital.

EKF Diagnostics Holdings plc Ron Zwanziger, Non-Executive Chairman Julian Baines, CEO	00 44 29 2071 0570 00 1 339 221 6282 00 44 7788 420 859
Panmure Gordon (UK) Limited Robert Naylor Paul Fincham	00 44 20 7886 2500
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

MEDLAB Dubai - Feb 2020

"The world's largest lab expo" - Medlab Middle East is a leading laboratory and flagship exhibition and Conference spanning across Middle East, Asia and West Europe.

AIM Awards 2019

EKF Diagnostics was delighted to win the AIM Transaction of the Year Award at the AIM Awards 2019.

New R&D facility in Head Office

Special Projects Laboratory opened in EKF’s Cardiff HQ to develop new applications in non-core markets and support other global diagnostics R&D facilities

Medica 2019

Medica is the world’s largest medical trade fair. For more than 40 years it has been firmly established on every professional's calendar attracting over 40,000 delegates and over 5,000 exhibitors from 70 countries in 17 halls.

EKF to highlight Lucica® Glycated Albumin-L assay for diabetes patient monitoring at AACC 2019

EKF announces the availability of a liquid, enzymatic test for glycated albumin (GA) that was recently FDA cleared for sales in the U.S. GA, used for intermediate term monitoring of glycemic control in diabetes patients, will be showcased at the 2019 AACC.